Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 20/20 | 1.00 |
| ▸ | GSK3B | P49841 | 18/20 | 1.00 |
| ▸ | WNT1 | P04628 | 13/20 | 1.00 |
| ▸ | CLK2 | P49760 | 2/20 | 0.56 |
| ▸ | CLK3 | P49761 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30003757 | 1.00 | DYRK1A (1.00) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL19517192 | 0.91 | DYRK1A (1.00) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL30003892 | 0.91 | DYRK1A (1.00) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL19517212 | 0.91 | DYRK1A (1.00) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL20951226 | 0.91 | DYRK1A (0.83) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL19516462 | 0.91 | GSK3B (1.00) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL30004872 | 0.91 | GSK3B (1.00) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL20949824 | 0.90 | DYRK1A (0.82) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL20946696 | 0.89 | DYRK1A (0.80) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL20950287 | 0.88 | DYRK1A (0.78) | DYRK1AGSK3BWNT1CLK2CLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4559905-A2 | ISOQUINOLIN-3-YL CARBOXAMIDES AS WNT INHIBITORS | BioSplice Therapeutics, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| US-12281097-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20230286945-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | TENARX, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230286945-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | TENARX, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230286945-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | TENARX, INC. | 2023-09-14 | — | — | US | disclosed |
| US-11548872-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-3892276-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AS WNT INHIBITORS | BioSplice Therapeutics, Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| EP-3892276-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AS WNT INHIBITORS | BioSplice Therapeutics, Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| CN-109310690-B | Isoquinolin-3-yl carboxamides, their preparation and their use | 萨穆梅德有限公司 | 2021-09-07 | — | — | CN | disclosed |
| US-10947217-B2 | Isoquinolin-3-YL carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2021-03-16 | — | — | US | disclosed |
| US-10100038-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2018-10-16 | — | — | US | disclosed |
| US-20180155323-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | TENARX, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20180155323-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | TENARX, INC. | 2018-06-07 | — | — | US | disclosed |
| US-9951048-B1 | Isoquinolin-3-yl carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951048-B1 | Isoquinolin-3-yl carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2018-04-24 | — | — | US | disclosed |
| US-20180093970-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | TENARX, INC. | 2018-04-05 | — | — | US | disclosed |
| US-20180093970-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | TENARX, INC. | 2018-04-05 | — | — | US | disclosed |
| WO-2017189829-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | SAMUMED, LLC (US) | 2017-11-02 | — | — | WO | disclosed |
| US-20170313682-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | TENARX, INC. | 2017-11-02 | — | — | US | disclosed |
| US-20170313682-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | TENARX, INC. | 2017-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12281097-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | WNT1, WNT3, WNT3A | DYRK1A 1006/4885GSK3B 5/4885WNT1 1/4885 |
| US-20180093970-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | WNT1, WNT3, WNT3A | DYRK1A 1006/4885GSK3B 5/4885WNT1 1/4885 |
| US-10947217-B2 | Isoquinolin-3-YL carboxamides and preparation and use thereof | WNT1, WNT3, WNT3A | DYRK1A 1006/4885GSK3B 5/4885WNT1 1/4885 |
| US-20230286945-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | WNT1, WNT3, WNT3A | DYRK1A 1006/4885GSK3B 5/4885WNT1 1/4885 |
| US-10100038-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | WNT1, WNT3, WNT3A | DYRK1A 1006/4885GSK3B 5/4885WNT1 1/4885 |
| US-11548872-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | WNT1, WNT3, WNT3A | DYRK1A 1006/4885GSK3B 5/4885WNT1 1/4885 |
| US-20180155323-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | WNT1, WNT3, WNT3A | DYRK1A 1006/4885GSK3B 5/4885WNT1 1/4885 |
| US-20170313682-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | WNT1, WNT3, WNT3A | DYRK1A 1006/4885GSK3B 5/4885WNT1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.